Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.42 |
| ▸ | CA1 | P00915 | 13/20 | 0.42 |
| ▸ | CA9 | Q16790 | 10/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA6 | P23280 | 3/20 | 0.42 |
| ▸ | CA5A | P35218 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31735982 | 0.84 | CA2 (0.45) | CA2CA1CA9CA12CA6 | |
| SCHEMBL18590932 | 0.84 | CA2 (0.45) | CA2CA1CA9CA12CA6 | |
| SCHEMBL21817054 | 0.74 | CA2 (0.42) | CA2CA1CA9CA12CA6 | |
| SCHEMBL21616543 | 0.72 | HTR2A (0.35) | — | |
| SCHEMBL9368882 | 0.71 | CA1 (0.57) | CA2CA1CA9CA12CA6 | |
| SCHEMBL31691307 | 0.70 | CA2 (0.40) | CA2CA1CA9CA12CA6 | |
| SCHEMBL15525070 | 0.68 | LMNA (0.43) | CA2CA1CYP2C9 | |
| SCHEMBL202947 | 0.67 | CA2 (0.70) | CA2CA1CA9CA12CA6 | |
| SCHEMBL31525276 | 0.67 | PKM (0.49) | CA2CA1CA9CA12CA4 | |
| SCHEMBL20153473 | 0.67 | PNMT (0.40) | CA2CA1CA9CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | CNR1, CDR2, SMN1; SMN2 | CA2 240/4885CA1 93/4885CA9 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.